Since PCSK9 inhibitors are not dependent on the hepatic CYP450 enzyme for metabolism, they may offer therapeutic advantages in patients with liver dysfunction or elevated baseline of ALT. This evidence concerns the gene PCSK9 and Decreased liver function.